Pleurodesis treatment with 50% glucose

Comparison of the results of pleurodesis treatment with 50% glucose with pleurodesis with bleomycin in patients with malignant pleural effusion referring to educational centers

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201013049017N1

Enrollment

Registered

2021-02-12

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pleural effusion. Malignant pleural effusion

Interventions

Intervention 1: Intervention group (A): There are 32 people in this group. the solution containing 200 cc of 50% glucose and 12.5 ml of 2% lidocaine is injected into the pleural cavity through the che

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with metastatic malignancies cause to pleural effusion. Diagnosis of malignant pleural effusion based on pleural fluid cytology. Symptomatic and recurrent pleural effusion due to malignancy. No history of allergy to bleomycin .

Exclusion criteria

Exclusion criteria: Reluctance to participate in the study

Design outcomes

Primary

Measure	Time frame
Investigation of the location and severity of pleural effusion. Timepoint: Before starting the intervention: Installation of chest tube number F 28 in the area of the hypothetical middle axillary line from the fifth or sixth intercostal space in the appropriate position24 to 48 hours after chest tube implantation: Preparation of chest graph in both face and profile positions. Method of measurement: CT-Scan.	—

Measure

Time frame

Investigation of the location and severity of pleural effusion. Timepoint: Before starting the intervention: Installation of chest tube number F 28 in the area of the hypothetical middle axillary line from the fifth or sixth intercostal space in the appropriate position24 to 48 hours after chest tube implantation: Preparation of chest graph in both face and profile positions. Method of measurement: CT-Scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthamid talebzadeh

Esfahan University of Medical Sciences

talebzadeh.h@med.mui.ac.ir+98 31 3237 8758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026